been looking all over for all comer trials…. There just isn’t a lot to be honest. Think that most biotechs and pharma for that matter are risk averse and simply hope a single indication shows efficacy. What does this say about Race’s confidence to run all comers trial, they are going all in!
Keytruda was one of a few all comer approvals and generally a subset biomarker or mutation. Rather than different cancer types. Expecting the readout won’t go unnoticed for long.
Intellectual Property (IP) Waterproofing., page-23
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.035(2.43%) |
Mkt cap ! $251.4M | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.48 | $1.44 | $11.37K | 7.761K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1348 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 800 | 1 |
View Market Depth
| Last trade - 10.27am 01/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |